Moderna, Inc. (MRNA) FY2025 Q1 P&L / Income Statement

Moderna, Inc. (MRNA) FY2025 Q1 P&L / Income Statement

Income statement for 2025-01-01 through 2025-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

108,000,000 US dollars

Cost of sales

90,000,000 US dollars

Gross profit (calculated)

18,000,000 US dollars

Operating expenses (calculated)

1,068,000,000 US dollars

Loss from operations

negative 1,050,000,000 US dollars

Other income (expense), net (calculated)

86,000,000 US dollars

Loss before income taxes

negative 964,000,000 US dollars

Provision for income taxes

7,000,000 US dollars

Net loss

negative 971,000,000 US dollars

Other revenue

22,000,000 US dollars

Net product sales - UNITED STATES

31,000,000 US dollars

Net product sales - Rest of world

55,000,000 US dollars

Net product sales - Europe

0 US dollars

Research and development

856,000,000 US dollars

Selling, general and administrative

212,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.